top of page

Sickle Cell Disease Treatment Market to Reach USD 19.69 Billion by 2034 at a 19.8% CAGR (2026–2034) 🧬💉

prajwal79
26 minutes ago
5 min read

The global sickle cell disease treatment market stood at USD 3.89 billion in 2025, is estimated at USD 4.65 billion in 2026, and is projected to reach USD 19.69 billion by 2034, registering a 19.8% compound annual growth rate (CAGR) over the 2026–2034 forecast period. Sickle cell disease (SCD) causes rigid, sickle-shaped red blood cells that can block small blood vessels, leading to painful vaso-occlusive crises (VOCs), anemia, and potential organ damage across the brain, lungs, and kidneys.

Therapeutic approaches for sickle cell disease treatment span pharmacotherapies such as hydroxyurea, L-glutamine (Endari), and crizanlizumab (Adakveo); blood transfusions for acute care and stroke prevention; hematopoietic stem cell transplantation (HSCT); and autologous gene therapies including Casgevy and Lyfgenia. Ex-vivo CRISPR gene editing of autologous hematopoietic stem cells paired with myeloablative Busulfan conditioning enables engrafted cells to generate red blood cells with elevated fetal hemoglobin (HbF), reducing sickling and painful crises.

In 2025, North America led the global market with a 42.8% revenue share, while blood transfusions accounted for a 32.6% segment share and hospitals captured a 46.8% end-use share. At the same time, regulatory milestones such as Casgevy label expansion alongside withdrawals and setbacks for Oxbryta (voxelotor) and Adakveo (crizanlizumab) highlight how clinical evidence and safety monitoring continue to reshape sickle cell disease care.

🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

Key Market Growth Drivers 🚀


  • Expansion of Newborn Screening Programs: Expanded newborn screening programs improve early identification of children with HbSS and HbSC genotypes, supported in India by initiatives like the National Sickle Cell Anemia Elimination Mission that strengthen early diagnosis and ongoing care demand.

  • Growing Gene Therapy Eligibility and Access: Advances in lentiviral vector gene addition and BCL11A enhancer modification that raise fetal hemoglobin (HbF) levels and curb hemoglobin S polymerization alongside autologous hematopoietic stem cell approaches are expanding eligible patient access and driving demand for gene therapy media and bioanalytical testing services.

  • Development of Oral Treatment Pipeline: New oral candidates, including pyruvate kinase (PKR) and PK activators such as mitapivat, etavopivat (ex-FT-4202), and tebapivat, aim to reduce pain episodes, improve daily management, and lower reliance on hospital-based care.

  • Support from the CMS Cell and Gene Therapy Access Model: The CMS Cell and Gene Therapy Access Model supports state-manufacturer discussions, outcomes-based rebates, and standardized pre-authorization at qualified treatment centers for eligible Medicaid and CHIP patients.

  • Rising R&D Investments and Disease Burden: Increasing research and development spending, growing awareness, and high disease burden including roughly 100,000 people living with the condition in the United States continue to propel sickle cell disease treatment adoption.


Key Market Dynamics ⚡


  • Blood Transfusion Leadership and Iron Overload Trade-Offs: Blood transfusion held a 32.6% market share in 2025 due to ongoing episodic and chronic transfusion needs, while repeated transfusions raise iron overload risks and support demand for iron chelation and blood management.

  • Hospital Dominance vs. Fast-Growing Specialty Clinics: Hospitals captured a 46.8% share in 2025 by providing specialized teams, transfusion infrastructure, stem cell transplantation, and gene therapy delivery, whereas specialty clinics are projected to grow at a 20.7% CAGR as patients seek dedicated monitoring, pain care, and follow-up.

  • Divergent Regional Growth and Revenue Realities: North America held a 42.8% share in 2025 on early therapy adoption and FDA approvals, Europe is projected at an 18.9% CAGR, Latin America held an 8.4% share in 2025, Middle East & Africa is projected at a 21.2% CAGR, and Asia Pacific is expected to record a 22.4% CAGR led by high burden in countries such as India.

  • Regulatory Approvals Alongside Safety Withdrawals: Casgevy (approved December 2023 for ages 12+ and expanded July 2026 in the U.S. to ages 2+, plus November 2026 MHRA extension to ages 5+ and NICE guidance update in England) and Lyfgenia (approved December 2023 for ages 12+) contrast with Pfizer's September 2024 global withdrawal of Oxbryta (voxelotor) and Adakveo's European authorization revocation following the Phase III STAND trial.


Market Challenges and Opportunities 🎯

Key Challenges ⚠️


  • High Cost of Advanced Treatments: High therapy costs such as approximately USD 2.2 million per dose for Casgevy and USD 3.1 million in the U.S. for Lyfgenia alongside stem cell harvesting, Busulfan conditioning, and limited insurance coverage restrict patient access.

  • Limited Treatment-Center Capacity: Specialized equipment, trained clinical teams, and cell manufacturing or long-term monitoring requirements limit the number of qualified treatment centers and lengthen patient wait times.

  • Limited Donor Availability and Blood Supply Constraints: Finding matched stem cell donors remains difficult, while blood unit shortages, alloimmunization, and tissue-matching complexities can disrupt transfusions and transplants.

  • Unequal Access to Treatment: Disparities in specialist availability, diagnostics, reimbursement, and awareness especially across rural, lower-income, and high-burden settings slow equitable care delivery.


Growth Opportunities 🌱


  • Expansion of Pediatric Gene Therapy: Expanding gene therapy eligibility to younger children such as Casgevy's U.S. expansion to ages 2 and older and MHRA extension to ages 5 and older creates early-intervention opportunities to reduce long-term complications.

  • Expansion of Screening Programs in India and Africa: Scaling newborn screening and early diagnosis across India backed by the National Sickle Cell Anemia Elimination Mission and Africa can connect more patients with timely therapies and care networks.

  • Adoption of Outcomes-Based Agreements: Outcomes-based payment models, including rebates negotiated under the CMS Cell and Gene Therapy Access Model, can help address high upfront costs and support broader adoption of curative and advanced therapies.


🌐𝐁𝐫𝐨𝐰𝐬𝐞 𝐅𝐮𝐥𝐥 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

Market Key Companies 🏢


  • Commercial Players: Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Genetix Biotherapeutics Inc. (formerly bluebird bio), Novartis AG, Emmaus Life Sciences, Inc., and Bristol Myers Squibb Company.

  • Pipeline and Other Notable Players: Pfizer Inc., Agios Pharmaceuticals, Inc., Novo Nordisk A/S, and Beam Therapeutics Inc., alongside diagnostics and coalition developments involving OraSure Technologies joining the World Coalition on Sickle Cell Disease in November 2026.


Market Segmentation 🧩


  • By Treatment: Blood Transfusion (32.6% share in 2025), Pharmacotherapy (18.9% projected CAGR, covering Hydroxyurea and Branded Drugs including Endari, Adakveo, Oxbryta, Zynteglo, CTX001, Mitapivat, and FT-4202), Hematopoietic Stem Cell Transplantation (17.6% projected CAGR), Gene Therapy (25.8% projected CAGR), and Bone Marrow Transplant.

  • By End-Use: Hospitals (46.8% share in 2025), Specialty Clinics (20.7% projected CAGR), and Others.

  • By Region: North America (42.8% share in 2025; U.S., Canada), Europe (18.9% projected CAGR; Germany, France, UK, Italy, Spain, Netherlands, Russia, Rest of Europe), Asia Pacific (22.4% projected CAGR; China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam, Rest of Asia Pacific), Middle East & Africa (21.2% projected CAGR; Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East & Africa), and Latin America (8.4% share in 2025; Mexico, Brazil, Argentina, Rest of Latin America).


Market Trends 📈


  • Rapid Expansion in Gene and Cell Therapies: Gene therapy is projected to grow at a 25.8% CAGR while hematopoietic stem cell transplantation grows at a 17.6% CAGR, supported by clinical milestones such as Beam Therapeutics reporting positive Phase I/II BEACON results for risto-cel (ex-BEAM-101) in November 2026 and late-stage oral candidates like Novo Nordisk's etavopivat (Phase III HIBISCUS in April 2026) and Agios's mitapivat and tebapivat.

  • Shift Toward Earlier Screening and Point-of-Care Diagnostics: Newborn screening expansion and point-of-care testing initiatives such as OraSure Technologies joining the World Coalition on Sickle Cell Disease are strengthening earlier detection and patient referrals.

  • Growing Role of Specialty Clinics Alongside Hospitals: Dedicated specialty clinics are expanding at a 20.7% CAGR to provide continuous monitoring, pain management, and long-term care alongside hospitals.

  • Focus on Payer Access and Outcomes-Based Models: Healthcare systems and payers are increasingly evaluating outcomes-based agreements and CMS access models to balance high gene therapy pricing with long-term clinical value.


Future Outlook 🔮

From USD 3.89 billion in 2025 and USD 4.65 billion in 2026 to a projected USD 19.69 billion by 2034 at a 19.8% CAGR, the sickle cell disease treatment market is set for substantial expansion driven by newborn screening, oral and gene-based innovations, and broader clinical awareness. Sustaining this momentum across North America, Asia Pacific, Europe, Middle East & Africa, and Latin America will depend on overcoming high treatment costs, expanding qualified treatment centers and blood supply reliability, and widening equitable access for patients.

 
 
 

Comments


Stay Informed with Our Latest Articles

500 Terry Francine Street, 6th Floor, San Francisco, CA 94158

bottom of page